Radiofrequency and microwave ablation in combination with transarterial chemoembolization induce equivalent histopathologic coagulation necrosis in hepatocellular carcinoma patients bridged to liver transplantation

被引:34
|
作者
Vasnani, Raj [1 ]
Ginsburg, Michael [1 ]
Ahmed, Osman [1 ]
Doshi, Taral [1 ]
Hart, John [2 ]
Te, Helen [3 ]
Thuong Gustav Van Ha [1 ]
机构
[1] Univ Chicago Med, Dept Radiol, Sect Vasc & Intervent Radiol, 5841 S Maryland Ave,MC2026, Chicago, IL 60367 USA
[2] Univ Chicago Med, Dept Pathol, Chicago, IL 60367 USA
[3] Univ Chicago Med, Dept Med, Gastroenterol Sect, Chicago, IL 60367 USA
关键词
Hepatocellular carcinoma (HCC); chemoembolization; radiofrequency; microwave; ablation; PERCUTANEOUS MICROWAVE; MULTIMODALITY TREATMENT; THERAPY; STANDARDIZATION; TERMINOLOGY; MALIGNANCY; RESECTION; CT;
D O I
10.21037/hbsn.2016.01.05
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Bridging therapy plays an increasingly important role in the management of patients with hepatocellular carcinoma (HCC) awaiting liver transplantation (LT). Combination therapy with drug-eluting bead transarterial chemoembolization (DEB-TACE) and percutaneous thermal ablation, such as radiofrequency ablation (RFA) or microwave ablation (MWA), has shown success at prolonging survival and bridging patients to LT. However, few studies have evaluated the two combination therapy regimens head-to-head at a single institution, and fewer have compared histopathology. This retrospective study compares tumor coagulation on explanted livers in patients with HCC treated with DEB-TACE sequentially combined with RFA versus MWA. Methods: From 2005 to 2015, 42 sequential patients underwent combination therapy prior to LT by Milan criteria, with 11 patients (11 tumors; mean, 2.9 cm; range, 1.8-4.3 cm) in the DEB-TACE/RFA cohort and 31 patients (40 tumors; mean, 2.4 cm; range, 1.1-5.4 cm) in the DEB-TACE/MWA cohort. The mean TACE procedures in the RFA and MWA cohorts were 1.3 (range, 1-2) and 1.3 (range, 1-3), respectively. The mean thermal ablations in the RFA and MWA cohorts were 1.2 (range, 1-2) and 1.3 (range, 1-3), respectively. Tumor coagulation was evaluated on explanted livers. Results: Mean tumor coagulation in the RFA and MWA cohorts were 88.9% (range, 0-100%) and 90.5% (range, 30-100%), respectively (P=0.82). Rates of complete tumor coagulation in the RFA and MWA cohorts were 45% and 53%, respectively (P=0.74). No difference in tumor coagulation was found between the cohorts when separating tumors <3 cm (P=0.21) and >3 cm (P=0.09). Among all 51 tumors, the 36 in complete response (CR) on imaging at LT demonstrated mean tumor coagulation of 95.8%. No correlation was found between tumor coagulation and initial tumor size or time interval to LT. No tumor seeding was seen along the ablation tracts. Conclusions: RFA and MWA in sequential combination with DEB-TACE, used as a bridge to LT, are equally efficacious at inducing HCC tumor coagulation.
引用
收藏
页码:225 / 233
页数:9
相关论文
共 50 条
  • [31] Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation
    DuBay, Derek A.
    Sandroussi, Charbel
    Kachura, John R.
    Ho, Chia Sing
    Beecroft, J. Robert
    Vollmer, Charles M.
    Ghanekar, Anand
    Guba, Markus
    Cattral, Mark S.
    McGilvray, Ian D.
    Grant, David R.
    Greig, Paul D.
    HPB, 2011, 13 (01) : 24 - 32
  • [32] Gallbladder actinomycosis: Is it a complication after radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma?
    Han, Hyung Joon
    Choi, Sae Byeol
    Kim, Wan Bae
    Song, Tae Jin
    Choi, Sang Yong
    CENTRAL EUROPEAN JOURNAL OF MEDICINE, 2011, 6 (03): : 300 - 304
  • [33] CT-guided Interstitial Brachytherapy of Hepatocellular Carcinoma before Liver Transplantation: an Equivalent Alternative to Transarterial Chemoembolization?
    Denecke, Timm
    Stelter, Lars
    Schnapauff, Dirk
    Steffen, Ingo
    Sinn, Bruno
    Schott, Eckart
    Seidensticker, Ricarda
    Puhl, Gero
    Gebauer, Bernhard
    Haenninen, Enrique Lopez
    Wust, Peter
    Neuhaus, Peter
    Seehofer, Daniel
    EUROPEAN RADIOLOGY, 2015, 25 (09) : 2608 - 2616
  • [34] Combining Transarterial Chemoembolization With Radiofrequency Ablation for Hepatocellular Carcinoma: One Step Forward?
    Zhu, Andrew X.
    Salem, Riad
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04) : 406 - 408
  • [35] Medium or Large Hepatocellular Carcinoma: Sorafenib Combined with Transarterial Chemoembolization and Radiofrequency Ablation
    Zhu, Kangshun
    Huang, Jingjun
    Lai, Lisha
    Huang, Wensou
    Cai, Mingyue
    Zhou, Jingwen
    Guo, Yongjian
    Chen, Junwei
    RADIOLOGY, 2018, 288 (01) : 300 - 307
  • [36] Transarterial Chemoembolization Followed by Radiofrequency Ablation for Hepatocellular Carcinoma: Impact of the Time Interval between the Two Treatments on Outcome
    Liu, Dan
    Liu, Ming
    Su, Liya
    Wang, Yu
    Zhang, Xiaoer
    Long, Haiyi
    Kuang, Ming
    Xie, Xiaoyan
    Lin, Manxia
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2019, 30 (12) : 1879 - 1886
  • [37] Transarterial Chemoembolization Combined with Microwave Ablation in Elderly Patients with Recurrent Medium or Large Hepatocellular Carcinoma
    Zhang, Chuxiao
    Qin, Yuelan
    Song, Yangguang
    Liu, Yingying
    Zhu, Xiaodong
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 2005 - 2017
  • [38] Changes in immunological function after treatment with transarterial chemoembolization plus radiofrequency ablation in hepatocellular carcinoma patients
    Guan Hai-tao
    Wang Jian
    Yang Ming
    Song Li
    Tong Xiao-qiang
    Zou Ying-hua
    CHINESE MEDICAL JOURNAL, 2013, 126 (19) : 3651 - 3655
  • [39] Impact of Multiple Transarterial Chemoembolization Treatments on Hepatocellular Carcinoma for Patients Awaiting Liver Transplantation
    Lai, Quirino
    Lerut, Jan
    LIVER TRANSPLANTATION, 2016, 22 (01) : 136 - 137
  • [40] Utility of percutaneous radiofrequency ablation alone or combined with transarterial chemoembolization for early hepatocellular carcinoma
    Tamai, Tsutomu
    Oshige, Akihiko
    Tabu, Kazuaki
    Tabu, Eriko
    Ijyuin, Syo
    Sakae, Haruka
    Onishi, Hiroka
    Muromachi, Kaori
    Saisyoji, Akiko
    Oda, Kohei
    Kumagai, Kotaro
    Mawatari, Seiichi
    Moriuchi, Akihiro
    Sakurai, Kazuhiro
    Hori, Tsuyoshi
    Ido, Akio
    ONCOLOGY LETTERS, 2017, 14 (03) : 3199 - 3206